Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-5083 in Lymphoid Hematological Malignancies
NCT02223598Phase 1Terminated
- Sponsor
- Cleave Therapeutics
- Start
- Aug 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of CB-5083 in hematological malignancy of lymphoid origin, multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL) and 1 more (3 arms), sponsored by Cleave Therapeutics. Primary endpoints: Dose Limiting Toxicities at 28 days, Area Under the Curve and 5 more. Started Aug 2014; status: terminated.
02
Drugs
CB-5083
03
Conditions
hematological malignancy of lymphoid originmultiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02223598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223598.